ethyl 1-(2-dimethylaminoethyl)-4,5,6,7-tetrahydro-3-methyl-4-oxo-6-phenyl-indole-2-carboxylate [ethyl 1-(2-dimethylaminoethyl)-4,5,6,7-tetrahydro-3-methyl-4-oxo-6-phenyl-indol-2-carboxylate] | 24353-47-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl 1-(2-dimethylaminoethyl)-4,5,6,7-tetrahydro-3-methyl-4-oxo-6-phenyl-indole-2-carboxylate [ethyl 1-(2-dimethylaminoethyl)-4,5,6,7-tetrahydro-3-methyl-4-oxo-6-phenyl-indol-2-carboxylate]
• 英文别名: 1-(2-dimethaneylaminoethyl)-4,5,6,7-tetrahydro-3-methyl-4-oxo-6-phenyl-indole-2-carboxylic acid ethyl ester；1-(2-dimethylaminoethaneyl)-4,5,6,7-tetrahydro-3-methyl-4-oxo-6-phenyl-indole-2-carboxylic acid ethyl ester；1-(2-dimethylaminoethyl)-4,5,6,7-tetrahydro-3-methyl-4-oxo-6-phenyl-indole-2-carboxylic acid ethyl ester；ethyl 1-(2-dimethylaminoethyl)-4,5,6,7-tetrahydro-3-methyl-4-oxo-6-phenyl-indol-2-carboxylate；ethyl-1-(2-dimethylaminoethyl)-4,5,6,7-tetrahydro-3-methyl-4-oxo-6-phenylindole-2-carboxylate；Ethyl 1-(2-dimethylaminoethyl)-4,5,6,7-tetrahydro-3-methyl-4-oxo-6-phenyl-indol-2-carboxylat；ethyl 1-[2-(dimethylamino)ethyl]-3-methyl-4-oxo-6-phenyl-6,7-dihydro-5H-indole-2-carboxylate
• CAS: 24353-47-7
• 化学式: C₂₂H₂₈N₂O₃
• 分子量: 368.476
• InChiKey: HCCJUDDYMVLQTC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  51.5
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Opioids for the treatment of the restless leg syndrome
  申请人：Euro-Celtique S.A.

  公开号：EP1604667A1

  公开（公告）日：2005-12-14

  The present invention relates to an opioid controlled release oral dosage form comprising at least one opioid for the manufacture of a medicament to treat patients with restless leg syndrome (RLS).

  本发明涉及一种包含至少一种阿片类药物的阿片类药物控释口服剂型，用于制造治疗不安腿综合征（RLS）患者的药物。
• Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
  申请人：Euro-Celtique S.A.

  公开号：EP1604666A1

  公开（公告）日：2005-12-14

  The present invention relates to an opioid controlled release oral dosage form comprising at least one opioid for the manufacture of a medicament to treat patients with Chronic Obstructive Pulmonary Disease (COPD).

  本发明涉及一种包含至少一种阿片类药物的阿片类药物控释口服剂型，用于制造治疗慢性阻塞性肺病（COPD）患者的药物。
• Matrix for sustained, invariant and independant release of active compounds
  申请人：EURO-CELTIQUE S.A.

  公开号：EP1639996A1

  公开（公告）日：2006-03-29

  The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics by ethylcellulose and at least one fatty alcohol. The invention also concerns methods for producing such pharmaceutical formulations.

  本发明涉及一种贮藏稳定的药物制剂，该制剂最好由两种活性化合物组成，并置于非膨胀扩散基质中，其中的化合物以持续、不变的方式从基质中释放，如果存在多种化合物，则以独立的方式释放，基质由乙基纤维素和至少一种脂肪醇决定其实质性释放特性。本发明还涉及生产这种药物制剂的方法。
• Opioids for the treatment of the chronic obstructive pulmonary disease (COPD)
  申请人：EURO-CELTIQUE S.A.

  公开号：EP1961421A1

  公开（公告）日：2008-08-27

  The present invention relates to an opioid controlled release oral dosage form comprising at least one opioid for the manufacture of a medicament to treat patients with Chronic Obstructive Pulmonary Disease (COPD).

  本发明涉及一种包含至少一种阿片类药物的阿片类药物控释口服剂型，用于制造治疗慢性阻塞性肺病（COPD）患者的药物。
• Non-invasive direct delivery of opioids to the central nervous system
  申请人：EURO-CELTIQUE S.A.

  公开号：EP2039360A1

  公开（公告）日：2009-03-25

  The present invention relates to opioid formulations for treating pain.

  本发明涉及用于治疗疼痛的阿片制剂。